Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraSphere followed by Imfinzi + Imjudo in hepatocellular carcinoma
2023-508945-41-00Phase 2Authorised
- Sponsor
- Biocompatibles
- Start
- Nov 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90, durvalumab and tiragolumab in hepatocellular carcinoma (HCC), sponsored by Biocompatibles. Primary endpoints: Objective response rate by mRECIST and Adverse events and serious adverse events. Planned start Nov 2023; status: authorised.
02
Drugs
yttrium-90durvalumabtiragolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-508945-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508945-41-00.